MEASURING THE VALIDITY AND RELIABILITY OF VALUE ASSESSMENT FRAMEWORKS FOR CANCER DRUGS- AN EVALUATION METHOD

Author(s)

Bentley TG1, Cohen JT2, Elkin EB3, Huynh J4, Mukherjea A5, Neville TH6, Mei MG7, Copher R8, Knoth RL8, Popescu I6, Lee J1, Zambrano JM1, Broder MS1
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Tufts Medical Center, Boston, MA, USA, 3Memorial Sloan-Kettering Cancer Center, New York, CA, USA, 4Hematology Oncology Medical Group of San Fernando Valley, Encino, CA, USA, 5California State University, East Bay, Hayward, CA, USA, 6David Geffen School of Medicine at UCLA, Department of Medicine, Los Angeles, CA, USA, 7City of Hope National Medical Center, Duarte, CA, USA, 8Eisai Inc., Woodcliff Lake, NJ, USA

Presentation Documents

OBJECTIVES: We aimed to develop a methodology for evaluating convergent validity and inter-rater reliability of value assessment frameworks. METHODS: Framework convergent validity, defined as the correlation among drug rankings across frameworks, can be assessed using Kendall’s W coefficient. Framework reliability is evaluated using intraclass correlation coefficients (ICC), which measure the stability of outcomes across users. Drugs can be assessed by independent physician and non-physician evaluators, who can use published drug trial data and instructions provided by framework developers to assign each drug a numeric or letter score. Mean scores for drugs within pre-defined categories (e.g., condition; indication) are rank-ordered to estimate Kendall’s W

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Value in Health, Vol. 20, No. 5 (May 2017)

Code

PRM167

Topic

Study Approaches

Disease

Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×